Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How important is hyperglycemia during acute brain infarction?

Askiel Bruno1, Linda S Williams, Thomas A Kent

  • 1Department of Neurology, Indiana University School of Medicine, Indianapolis, 46202, USA. abruno@iupui.edu

The Neurologist
|July 13, 2004
PubMed
Summary

Lowering high blood sugar (hyperglycemia) during acute cerebral infarction may improve patient outcomes. Clinical trials are underway to confirm if tight glycemic control benefits patients with acute stroke.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A brief novel questionnaire to estimate premorbid functional state in acute stroke patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Transcriptomic and proteomic evidence for noncanonical hydrogen sulfide metabolism and immune dysregulation in Down Syndrome.

Scientific reports·2026
Same author

Multifunctional nanozyme therapy accelerates hematoma clearance and attenuates genome damage and senescence after intracerebral hemorrhage.

bioRxiv : the preprint server for biology·2026
Same author

<i>SOD1</i> at the Crossroads: Co-Overexpression of Canonical Antioxidant Response and Noncanonical Hydrogen Sulfide Generation Pathways in Down Syndrome, With Immune Cell Implications.

Research square·2026
Same author

Documented goals of care conversations with hospitalized patients after severe stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same author

Impact of the Veterans Affairs National Telestroke Program's Subacute Telestroke Service on Interhospital Transfers.

The Neurohospitalist·2025

Area of Science:

  • Neurology
  • Endocrinology
  • Ischemic Stroke Research

Background:

  • Animal studies suggest hyperglycemia worsens brain injury during acute cerebral infarction, particularly with reperfusion.
  • Clinical evidence from myocardial infarction and postsurgical patients indicates improved outcomes with hyperglycemia reduction.
  • Existing human studies on acute cerebral infarction are observational, linking hyperglycemia to poorer outcomes.

Purpose of the Study:

  • To evaluate the potential benefits of lowering hyperglycemia in acute cerebral infarction.
  • To determine if tight glycemic control improves outcomes compared to persistent hyperglycemia.
  • To justify the resources required for intensive glycemic management in stroke patients.

Main Methods:

  • Review of animal studies on hyperglycemia and brain ischemia with reperfusion.

Related Experiment Videos

  • Analysis of observational human studies correlating hyperglycemia with acute cerebral infarction outcomes.
  • Consideration of evidence regarding hyperglycemia's role in thrombolytic-induced hemorrhagic conversion.

    • Main Results:

    • Hyperglycemia appears detrimental in acute brain ischemia models with reperfusion.
    • Observational data consistently associate hyperglycemia with worse outcomes in acute cerebral infarction.
    • A linear relationship exists between glucose levels and adverse outcomes.
    • Hyperglycemia is linked to hemorrhagic conversion when thrombolytics are used.

    Conclusions:

    • Sufficient evidence supports initiating clinical trials for tight glycemic control in acute cerebral infarction.
    • Successful trials could justify the costs and risks of intensive glucose management.
    • Randomized clinical trials are currently in progress to test this therapeutic hypothesis.